Assembly Biosciences Inc. (ASMB)
Assembly Biosciences: Gilead Advancements For GS-1179 And ABI-6250 Is A Bullish Signal
Assembly Biosciences is maintained at a 'Buy' rating, driven by pipeline advancement and a strong cash position. Key catalysts include phase 2 trials for GS-1179 in genital herpes and ABI-6250 in chronic HDV, PBC, and PSC, with multiple readouts expected 2027–2028. ASMB's partnership with Gilead on GS-1179 offers strategic optionality between milestone/royalty payments or a 40% cost-profit share.
Assembly Biosciences (ASMB) Reports Q2 Loss, Beats Revenue Estimates
Assembly Biosciences (ASMB) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.33 per share a year ago.
Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates
Assembly Biosciences has evolved into a strategically financed antiviral platform, underpinned by a robust partnership with Gilead and a strengthened balance sheet. ASMB's pipeline targets high-unmet-need indications—recurrent genital herpes, HDV, and cholestatic liver diseases—with differentiated mechanisms and strong early clinical data. Pro forma liquidity exceeds $340 million post-offering, supporting operations through 2028 and enabling strategic optionality without near-term capital needs.
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
Assembly Biosciences NASDAQ: ASMB outlined its antiviral and liver disease development strategy during a fireside chat at the 47th Annual Goldman Sachs Healthcare Conference, highlighting upcoming decisions tied to its herpes simplex virus type 2 program, expansion of its hepatitis delta candidate into cholestatic liver diseases and expected clinical data readouts in 2027 and 2028.
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
Assembly Biosciences NASDAQ: ASMB is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event.
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
Assembly Biosciences (ASMB) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to a loss of $1.17 per share a year ago.
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences (ASMB) came out with quarterly earnings of $2.48 per share, beating the Zacks Consensus Estimate of a loss of $0.51 per share. This compares to a loss of $1.57 per share a year ago.
Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript
Assembly Biosciences, Inc. (ASMB) Discusses Positive Interim Results for ABI-1179 and ABI-5366 in Recurrent Genital Herpes Phase 1b Studies Transcript
Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts
Assembly Biosciences, Inc.'s ABI-5366 showed strong interim phase 1b results in HSV-2 recurrent genital herpes patients, with a 94% reduction in HSV-2 shedding and genital lesion rates. Upcoming catalysts include monthly dosing data for ABI-5366 and phase 1b data for ABI-1179, both expected in fall 2025, plus potential Gilead opt-in milestones. ASMB addresses a major unmet need, as no new HSV-2 therapies have been approved in 25+ years and the market could reach $4B by 2030.
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Assembly Biosciences (ASMB) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $2.01. This compares to loss of $1.66 per share a year ago.
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
Assembly Biosciences (ASMB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Assembly Biosciences (ASMB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
